Skip to content

This is a promotional website fully funded and created by SERB Pharmaceuticals for UK Healthcare Professionals only.

Order Voraxaze

This is a promotional website intended for licensed healthcare professionals
or prescribed patients in the United Kingdom or Republic of Ireland.
Please select one of the following:

I am a patient

Continue

I am a Healthcare Professional

Outside of the UK

United States (EN) Germany (DE)

I am a Healthcare Professional
In the UK

UK-VRX-2600029 Date of Last Revision: April 2026

Patient Characteristics

Patients Characteristics1

Patients receiving Voraxaze® with:

  • No pre-existing grade 4 toxicity before Voraxaze® administration
  • The appropriate increase in leucovorin rescue within 3 days after the start of HDMTX infusion
 

Administration of Voraxaze®

  • ≤ 96 hours after HDMTX exposure, n = 64
  • 96 hours after HDMTX exposure, n = 11

Inclusion Criteria1

Patients with MTX-induced nephrotoxicity and delayed MTX excretion were eligible for treatment with Voraxaze®, if either of the following two conditions were met:

  • Plasma MTX concentration was ≥10 μmol/L ≥42 hours after the start of HDMTX infusion
  • sCr was ≥1.5 times the upper limit of normal or CrCl was ≤ 60mL/min/m2sup> and the plasma MTX concentration was ≥2 standard deviations above the mean ≥12 hours after MTX administration

Abbreviations: CrCl, creatinine clearance; HDMTX, high dose methotrexate; MTX, methotrexate; sCr, serum creatinine.

References

  1. Widemann BC, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010;28(25):3979-86.

UK-VRX-2600033 Date of Last Revision: February 2026